Solventum (NYSE:SOLV) Given New $73.00 Price Target at Morgan Stanley

Solventum (NYSE:SOLV) had its price target hoisted by Morgan Stanley from $60.00 to $73.00 in a research note published on Monday,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other equities analysts also recently issued reports on SOLV. BTIG Research initiated coverage on shares of Solventum in a research note on Thursday, September 5th. They set a “neutral” rating on the stock. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Wells Fargo & Company reduced their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. Piper Sandler increased their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Finally, The Goldman Sachs Group increased their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Solventum currently has a consensus rating of “Hold” and an average target price of $68.00.

Solventum Price Performance

Solventum stock opened at $67.93 on Monday. The firm has a 50-day moving average of $70.46 and a two-hundred day moving average of $62.17. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum has a 1 year low of $47.16 and a 1 year high of $96.05.

Institutional Investors Weigh In On Solventum

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Solventum by 4.2% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after purchasing an additional 200 shares during the period. National Bank of Canada FI raised its stake in shares of Solventum by 4.0% in the second quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock valued at $314,000 after acquiring an additional 236 shares in the last quarter. IVC Wealth Advisors LLC increased its holdings in Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after purchasing an additional 318 shares during the period. KKM Financial LLC boosted its stake in shares of Solventum by 7.9% in the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock valued at $304,000 after buying an additional 319 shares during the period. Finally, Copeland Capital Management LLC acquired a new position in Solventum during the 3rd quarter worth approximately $26,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.